Speciality European Pharma, the Pan European Specialty Urology Company, Acquires Mitem(R)
Mitem is an injectable mitomycin product used either on its own or in combination with other therapies in the treatment of a range of cancers. Most notably Mitem is given intravesically (into the bladder) for the treatment of bladder cancer.
Commenting on the acquisition, Geoff McMillan, Chief Executive Officer of SEP, said:
“This acquisition further enhances SEP’s product offerings to the urologist and is another milestone in the Company’s development as a pan European urology company. It is the Company’s fourth specialist urology product, the others being Plenaxis® for the treatment of prostate cancer and Regurin® and Regurin® XL each for the treatment of overactive bladder.”
About Mitem
Mitem is a powdered form of mitomycin, a cytotoxic medicine used in the treatment of a variety of cancers, including bladder cancer. Mitomycin products have been on the market for many years and in Germany, the largest European market for mitomycin products, they represent the standard treatment for patients with low risk bladder cancer. Intravesical therapy with Mitem is frequently used as adjuvant treatment in patients with superficial bladder cancer. Compared with surgery alone, surgery plus intravesical mitomycin has been shown to cause tumour regression and to reduce the rate of short-term tumour recurrence.
About Speciality European Pharma
Founded in April 2006, SEP is a privately owned speciality pharmaceutical company. Its mission is to become the leading Urologist focused Specialty pharmaceutical business in Europe.
SEP owns worldwide rights to Plenaxis®, the world’s first approved GnRH blocker for the treatment of prostate cancer. Plenaxis gives a rapid and sustained decline in testosterone levels, which gives quick and sustained control of prostate cancer and its symptoms. Plenaxis was launched in Germany in February 2008.
SEP has distribution rights in the UK and the Republic of Ireland for two products, Regurin® and Regurin® XL, respectively twice daily and once daily treatments for overactive bladder.
SEP has distribution rights in France and Italy for Haemopressin®, a product for the treatment of bleeding oesophageal varices. This product is delivered to clinicians in a hospital setting.
SEP has established its own commercial operations in the UK, Germany, France and Italy and will market its products in other regions and territories through relationships with expert partners.
Contact Josephine Salm Grayling +44 (0)20 7592 7930 Josephine.Salm@grayling.com
News Receiver Options Receivers members area – the receivers members area allows you to amend your news category options and preferences, and access your own personal RSS feed of relevant news. Log in now or request log in details. Unsubscribe – should you wish to unsubscribe from RealWire’s distribution, please click here. We would very much value your feedback on why you wish to be removed in order for us to continue to improve and develop our service.
Disclaimer: Whilst RealWire Limited endeavour to ensure the accuracy of the information contained in this Release, RealWire Limited cannot accept any liability for:-
• the inaccuracy or otherwise of any information contained in this Release; or
• any loss liability or expense which may be suffered by any party in consequence of acting or omitting to act as a result of any information contained in or omitted from this Release; or
• any loss or suffering which may be caused by or to any party either as a result of the information contained in this Release or such information contained in this Release being inaccurate or otherwise misleading.
In the event that any information contained in this Release is inaccurate or misleading then please contact RealWire.
RealWire’s privacy policy is available on our website.
RealWire: The registered address of RealWire is: Realwire Limited, Unit 1, Exchange Close, North Hykeham, Lincoln, LN6 3TR. Realwire Limited is a company registered in England and Wales: 4026690